The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Multiple sclerosis: Pathology, diagnosis and treatments
Open accessAbstract
Multiple sclerosis (MS) is a complex neurodegenerative disease affecting the central nervous system (CNS). The onset of MS has been typically observed in individuals aged from 20 to 40-years, with the female to male ratio of 1:2. MS appears as abrupt onset of focal sensory disturbances that is accompanied by unilateral painless damage of vision, double vision, limb weakness, unsteadiness of gait, and bowel or bladder symptoms. Whereas the exact etiology of the disease is unknown, observational research has suggested genetic and environment influences through an underlined pathophysiology widely believed to be autoimmune in nature. Indeed, plaque of demyelination inside of the CNS with relative conservation of axons remains the clinical symptoms of MS. However, considerable advances in understanding the pathology have contributed to an early diagnosis, particularly the exact neuroanatomical setting of plaques. Accordingly, magnetic resonance imaging has been considered as the primarily adjunctive modality for the constant detection of abnormal white matter. In addition, the analysis of cerebrospinal fluid contents has also been of interest for the diagnosis to discriminate other affections such infection or vasculitis. These resulted in a broad variety of therapies that considerably control the activity and change the course and prognosis of the disease. In the present review, we evaluate the current state of knowledge on MS with emphasis on the pathology itself, the diagnosis and common therapeutical approaches accurately used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
The changing demographic pattern of multiple sclerosis epidemiology
Koch-Henriksen, N., & Sørensen, P. S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70064-8 · Cited by 1,191
Pathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Environmental risk factors for multiple sclerosis. Part I: The role of infection
Ascherio, A., & Munger, K. L. (2007) · Annals of Neurology · doi:10.1002/ana.21117 · Cited by 1,042
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898
Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T. A., McFarland, H., Henkart, P. A., & Martin, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601335103 · Cited by 597
Bjartmar, C., Wujek, J. R., & Trapp, B. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00069-2 · Cited by 573
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Chataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C. R. M., Clegg, S., Nielsen, C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62242-4 · Cited by 443
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 398
Analysis of regulatory CD8 T cells in Qa-1-deficient mice
Hu, D., Ikizawa, K., Lu, L., Sanchirico, M. E., Shinohara, M. L., & Cantor, H. (2004) · Nature Immunology · doi:10.1038/ni1063 · Cited by 330
Revised diagnostic criteria of multiple sclerosis
Milo, R., & Miller, A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.012 · Cited by 326
HL-A ANTIGENS AND MULTIPLE SCLEROSIS
Jersild, C., Svejgaard, A., & Fog, T. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90962-2 · Cited by 324
Traugott, U., Reinherz, E. L., & Raine, C. S. (1983) · Journal of Neuroimmunology · doi:10.1016/0165-5728(83)90036-x · Cited by 315
Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS
Van Der Valk, P., & De Groot, C. J. A. (2000) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2000.00217.x · Cited by 306
Soilu-Hänninen, M., Åivo, J., Lindström, B.-M., Elovaara, I., Sumelahti, M.-L., Färkkilä, M., Tienari, P., Atula, S., Sarasoja, T., Herrala, L., et al. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301876 · Cited by 269
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis
Stein, M. S., Liu, Y., Gray, O. M., Baker, J. E., Kolbe, S. C., Ditchfield, M. R., Egan, G. F., Mitchell, P. J., Harrison, L. C., Butzkueven, H., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182343274 · Cited by 185
Neuronal injury in chronic CNS inflammation
Zindler, E., & Zipp, F. (2010) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2010.11.001 · Cited by 160
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice
de, J., Airas, L. M., Bartholome, E. J., Grigoriadis, N., Mattle, H. P., Oreja‐Guevara, C., O’Riordan, J. I., Sellebjerg, F. T., Stankoff, B., Vass, K., et al. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611403646 · Cited by 116
Progressive multiple sclerosis
Ontaneda, D., & Fox, R. J. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000195 · Cited by 100
Gold, J., Goldacre, R., Maruszak, H., Giovannoni, G., Yeates, D., & Goldacre, M. J. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307932 · Cited by 95
Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis
Kurtzke, J. F. (2000) · Neurological Sciences · doi:10.1007/s100720070055 · Cited by 92
Shaygannejad, V., Janghorbani, M., Ashtari, F., & Dehghan, H. (2012) · Multiple Sclerosis International · doi:10.1155/2012/452541 · Cited by 76
Decoding multiple sclerosis: an update on genomics and future directions
Oksenberg, J. R. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.865867 · Cited by 70
The Clinical Neuropsychiatry of Multiple Sclerosis
Feinstein, A. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543760 · Cited by 67
Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades
Celius, E. G., & Smestad, C. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01208.x · Cited by 66
Mars, L., Bauer, J., Gross, D., Bucciarelli, F., Firat, H., Hudrisier, D., Lemonnier, F., Kosmatopoulos, K., & Liblau, R. (2007) · Journal of Immunology · doi:10.4049/jimmunol.179.8.5090 · Cited by 29
How can proteomics elucidate the complexity of multiple sclerosis?
Farias, A. S., & dos Santos, L. M. B. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400171 · Cited by 8
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Research works printed but not linked: 4
- Holland, 2014, Factors affecting quality of life in persons with multiple sclerosis
- Lucchinetti, 2000, Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination, Ann Neurol, 47, 707, 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q · DOI
- Mosayebi, 2011, Therapeutic effect of vitamin D3 in multiple sclerosis patients, Immunol Invest, 40, 627, 10.3109/08820139.2011.573041 · doi:10.3109/08820139.2011.573041
- BielekovaBCatalfamoMReichert-ScrivnerSPackerACernaMWaldmannTAMcFarlandHHenkartPAMartinRRegulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosisProc Natl Acad Sci USA10359415946200610.1073/pnas.060133510316585503 · doi:10.1073/pnas.060133510316585503
Cited by
In vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 290
Digital Twins for Multiple Sclerosis
Voigt, I., Inojosa, H., Dillenseger, A., Haase, R., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669811 · Cited by 272
Calina, D., Buga, A. M., Mitroi, M., Buha, A., Caruntu, C., Scheau, C., Bouyahya, A., El Omari, N., El Menyiy, N., & Docea, A. O. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082395 · Cited by 65
Almeida, M. N., Silvernale, C., Kuo, B., & Staller, K. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13592 · Cited by 34
White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
García-Domínguez, M. (2025) · Cells · doi:10.3390/cells14181408 · Cited by 13
“Histopathologically, MS is characterized by focal demyelinated plaques in the white and gray matter of the brain and spinal cord, associated with inflammation, gliosis, axonal transection, and neurodegeneration [17,18].”
Metadata
- Authors
- Huang, W.-J., Chen, W.-W., & Zhang, X.
- Venue
- Experimental and Therapeutic Medicine
- Publisher
- Spandidos Publications
- Published
- 2017-04-28
- Volume
- 13
- Issue
- 6
- Pages
- 3163-3166
- ISSN
- 1792-0981 (ISSN-L)
- 1792-1015
- OpenAlex
- W2609370764
- Cited by
- 351
- References
- 46
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.